Literature DB >> 15800327

Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor.

Achim Fleischmann1, George N Thalmann, Regula Markwalder, Urs E Studer.   

Abstract

PURPOSE: To analyze the prognostic impact of risk factors for urothelial carcinoma of the bladder (UCB) with pelvic lymph node (LN) metastases. PATIENTS AND METHODS: We analyzed a consecutive series of 507 patients with UCB who were preoperatively staged N0M0. One hundred one of 124 eligible patients who were treated with radical cystectomy and standardized extended bilateral pelvic lymphadenectomy with curative intent and had postoperatively confirmed LN metastases were evaluated in regard to recurrence-free and overall survival.
RESULTS: A median of 22 nodes per patient (range, 10 to 43 nodes) were removed and examined. Median recurrence-free and overall survival durations were 17 months and 21 months (range for both, 1 to 191 months), respectively. In the multivariate analysis for recurrence-free survival, extracapsular extension of LN metastases was the strongest prognostic factor (P = .019). Other variables such as tumor stage (pT1/2 v pT3 and pT4), the number (< five v >/= five), and the percentage (< 20% v >/= 20%) of metastatic nodes had a significant influence on recurrence-free and overall survival in the univariate analysis. However, they all failed to be significant prognostic factors in the multivariate analysis.
CONCLUSION: The results of this study indicate that radical cystectomy with bilateral lymphadenectomy can have a curative effect in a subset of patients with pelvic LN positive UCB. Provided that a representative number of LNs are removed by meticulous lymphadenectomy and that a thorough histologic examination is performed, prognosis for such patients can be determined quite reliably. In the multivariate analysis, extracapsular extension of LN metastases was the strongest factor predicting prognosis.

Entities:  

Mesh:

Year:  2005        PMID: 15800327     DOI: 10.1200/JCO.2005.03.084

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  42 in total

1.  Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients.

Authors:  Lauren C Harshman; Gerold Bepler; Zhong Zheng; John P Higgins; Genevera I Allen; Sandy Srinivas
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

2.  [Bladder cancer--what's new].

Authors:  J Gschwend
Journal:  Urologe A       Date:  2006-04       Impact factor: 0.639

Review 3.  [Standards and perspectives in diagnosis and therapy of bladder carcinoma].

Authors:  C Stief; D Zaak; M Stöckle; U Studer; R Knuechel; C Rödel; R Sauer; H Rubben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

4.  [Optimizing treatment of advanced urologic malignancies].

Authors:  A Heidenreich; C H Ohlmann; E Ozgür; D Pfister; D Sahi; D Thüer; U H Engelmann
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 5.  Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.

Authors:  Samdeep K Mouli; Lee C Zhao; Reed A Omary; C Shad Thaxton
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

6.  [Is there an indication for adjuvant or neoadjuvant systemic chemotherapy in bladder cancer?].

Authors:  H Suttmann; M Retz; J E Gschwend; M Stöckle
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

7.  Role of lymphadenectomy for invasive bladder cancer.

Authors:  Faysal A Yafi; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

8.  Role of pelvic lymphadenectomy in the treatment of bladder cancer: a mini review.

Authors:  Ja Hyeon Ku
Journal:  Korean J Urol       Date:  2010-06-21

Review 9.  DW-MRI of the urogenital tract: applications in oncology.

Authors:  G Petralia; H C Thoeny
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

10.  Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer.

Authors:  Roland Seiler; Michael von Gunten; George N Thalmann; Achim Fleischmann
Journal:  J Clin Pathol       Date:  2010-04-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.